Somerville, Massachusetts-based Finch Therapeutics Group Inc, a clinical-stage microbiome drug development company, has secured $90 million in Series D financing. The investors included Baupost Group, Humboldt Fund, MSD Capital, MSD Partners, Octave Group, OMX Ventures, Avenir Growth Capital, OCV Partners, Shumway Capital, SIG, SymBiosis, TPTF, and Willett Advisors.
Source: Press Release
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: